Eylea
Regeneron’s High-Dose Eylea Launch Takes Off, Rivals Roche’s Vabysmo
Roche’s increased sales for its extended-release treatment for macular degeneration, Vabysmo, indicate that consumers are willing to try new therapies. ...
Debbie Allen joins Regeneron and Prevent Blindness to launch the Gr8 Eye Movement and raise awareness of serious retinal diseases
Regeneron is adding a touch of star power to its efforts to promote eye health by enlisting the renowned actress, ...
Sandoz to market Samsung Bioepisā biosimilar of Stelara in US and Canada
Sandoz is expanding its biosimilar portfolio by signing a commercialization agreement with Samsung Bioepis for a biosimilar version of Johnson ...
FDA Approves Eylea HD Injection 8 mg for the Treatment of Wet Age-related Macular Degeneration, Diabetic Macular Edema, and Diabetic Retinopathy
On August 18, 2023, Regeneron Pharmaceuticals announced a groundbreaking development in the field of ophthalmology: the US Food and Drug ...
Regeneron Faces New Challenges as Biosimilars Target Eylea Market Dominance, Novartis’ Sandoz Takes Aim with Therapeutic Equivalence
Regeneron finds itself at a crossroads as its blockbuster eye drug Eylea contends with an FDA rejection and growing competition ...
Regeneron’s High-Dose Eylea Demonstrates Persistence as FDA Decision Looms
While awaiting an FDA decision regarding a higher-dose version of Eylea (aflibercept), Regeneron has consistently emphasized the durability of their ...
Vabysmo, Roche’s Top Eye Medicine, Crosses Blockbuster Threshold Ahead of Competitors
According to Roche’s pharma chief, Teresa Graham, their eye drug Vabysmo is currently experiencing significant momentum. Since its FDA approval ...
Catalentās Indiana Facility Faces FDA Observations After Eylea Rejection
Following an unexpected rejection from the FDA for Regeneron’s high-dose Eylea, the FDA disclosed issues related to cleaning and procedures ...
Regeneron has faced an unexpected rejection from the FDA for its high-dose version of Eylea due to manufacturing challenges
Source – Regeneron Regeneron’s highly anticipated high-dose version of Eylea has suffered an unexpected setback as the FDA rejected its ...
